Tocilizumab versus Rituximab in Patients with Moderate to Severe Steroid-resistant Graves' Orbitopathy

被引：18

作者：

Bennedjai, Amin ^{[1
]}

Bouheraoua, Nacim ^{[1
]}

Gatfosse, Marc ^{[2
,3
]}

Dupasquier-Fediaevsky, Laurence ^{[1
]}

Errera, Marie-Helene ^{[1
,4
]}

Tazartes, Michel ^{[1
]}

Borderie, Vincent ^{[1
]}

Hennocq, Quentin ^{[5
]}

Della, Azeddine ^{[6
]}

Riviere, Sebastien ^{[2
,3
]}

Heron, Emmanuel ^{[1
]}

Fain, Olivier ^{[2
,3
]}

Mekinian, Arsene ^{[2
,3
]}

机构：

[1] Sorbonne Univ, Ctr Hosp Natl Ophtalmol 15 20, F-75015 Paris, France

[2] Sorbonne Univ, Hop St Antoine, AP HP, Serv Med Interne & Inflammat Immunopathol Biother, Paris, France

[3] Sorbonne Univ, UPMC Univ Paris 06, UMR 7211, Dept Hosp Univ Inflammat Immunopathol Biotherapie, Paris, France

[4] Pittsburgh Univ Hosp, Montfermeil, PA USA

[5] Hop La Pitie Salpetriere, AP HP, Serv Chirurg Maxillofaciale, Paris, France

[6] Hop Montfermeil, Serv Rhumatol, Montfermeil, France

来源：

OCULAR IMMUNOLOGY AND INFLAMMATION | 2022年 / 30卷 / 02期

关键词：

Tocilizumab; rituximab; Graves's orbitopathy; outcome; MANAGEMENT; EFFICACY; SAFETY; THERAPY;

D O I：

10.1080/09273948.2020.1808688

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Introduction To describe the efficacy of tocilizumab in patients with Graves' orbitopathy resistant or dependent to steroids and compare to rituximab treated patients. Patients and Methods Graves's orbitopathy response was considered as decrease of at least 2 points of the CAS. Results Twenty-one patients were included, 7 patients were treated with tocilizumab and 14 with rituximab. The primary was achieved in all 7 patients (100%) on tocilizumab and 9 out of 14 patients on (64%) rituximab (p= .17). Mean change in CAS was consistent with a decrease of 3.3 +/- 0.5 points in patients on tocilizumab versus 2.5 +/- 1.9 in patients on rituximab (p= .07). One patient on tocilizumab (14%) and 4 patients (29%) on rituximab experienced significant relapse during the follow-up. The difference in relapse-free survival was not significant in patients on tocilizumab (10.8 +/- 4 months) compared with rituximab (17.88 +/- 3.66). Conclusion We showed a significant improvement in the CAS, visual acuity, diplopia, and proptosis with both tocilizumab and rituximab.

引用

页码：500 / 505

页数：6

共 19 条

[1] MECHANISMS OF DISEASE Graves' Ophthalmopathy [J].

Bahn, Rebecca S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (08) :726-738

[2] Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' Orbitopathy [J].

Bartalena, L. ;

Krassas, G. E. ;

Wiersinga, W. ;

Marcocci, C. ;

Salvi, M. ;

Daumerie, C. ;

Bournaud, C. ;

Stahl, M. ;

Sassi, L. ;

Veronesi, G. ;

Azzolini, C. ;

Boboridis, K. G. ;

Mourits, M. P. ;

Soeters, M. R. ;

Baldeschi, L. ;

Nardi, M. ;

Curro, N. ;

Boschi, A. ;

Bernard, M. ;

von Arx, G. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (12) :4454-4463

[3] Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of Graves' Orbitopathy [J].

Bartalena, Luigi ;

Baldeschi, Lelio ;

Dickinson, Alison J. ;

Eckstein, Anja ;

Kendall-Taylor, Pat ;

Marcocci, Claudio ;

Mourits, Maarten P. ;

Perros, Petros ;

Boboridis, Kostas ;

Boschi, Antonella ;

Curro, Nicola ;

Daumerie, Chantal ;

Kahaly, George J. ;

Krassas, Gerasimos ;

Lane, Carol M. ;

Lazarus, John H. ;

Marino, Michele ;

Nardi, Marco ;

Neoh, Christopher ;

Orgiazzi, Jacques ;

Pearce, Simon ;

Pinchera, Aldo ;

Pitz, Susanne ;

Salvi, Mario ;

Sivelli, Paolo ;

Stahl, Matthias ;

von Arx, Georg ;

Wiersinga, Wilmar M. .

THYROID, 2008, 18 (03) :333-346

[4] Low-Dose Rituximab for Active Moderate to Severe Graves' Orbitopathy Resistant to Conventional Treatment [J].

Du Pasquier-Fediaevsky, Laurence ;

Andrei, Stefan ;

Berche, Michel ;

Leenhardt, Laurence ;

Heron, Emmanuel ;

Riviere, Sebastien .

OCULAR IMMUNOLOGY AND INFLAMMATION, 2019, 27 (05) :844-850

[5]

Gomez Rodriguez Lourdes, 2014, Farm Hosp, V38, P448, DOI 10.7399/fh.2014.38.5.7574

[6]

Krieger CC, 2016, J CLIN ENDOCR METAB, V176

[7] Incidence and Clinical Presentation of Moderate to Severe Graves' Orbitopathy in a Danish Population before and after Iodine Fortification of Salt [J].

Laurberg, Peter ;

Berman, Dalia C. ;

Pedersen, Inge Bulow ;

Andersen, Stig ;

Carle, Allan .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (07) :2325-2332

[8] Interleukin-6 blockade in ocular inflammatory diseases [J].

Mesquida, M. ;

Leszczynska, A. ;

Llorenc, V. ;

Adan, A. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 176 (03) :301-309

[9] Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy [J].

Mourits, MP ;

Prummel, MF ;

Wiersinga, WM ;

Koornneef, L .

CLINICAL ENDOCRINOLOGY, 1997, 47 (01) :9-14

[10] Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial [J].

Perez-Moreiras, Jose, V ;

Gomez-Reino, Juan J. ;

Maneiro, Jose R. ;

Perez-Pampin, Eva ;

Romo Lopez, Angel ;

Rodriguez Alvarez, Fernando M. ;

Castillo Laguarta, Jesus M. ;

del Estad Cabello, Aurora ;

Gessa Sorroche, Maria ;

Espana Gregori, Enrique ;

Sales-Sanz, Marco .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2018, 195 :181-190

← 1 2 →